Wednesday, May 14, 2014 6:20:57 PM
Initiation of Bench and Pre-Clinical Tissue Testing (2H 2013)
•Tissue testing initiated
•Technical feasibility and integrated testing continues
Initiation of Pre-clinical and Clinical Planning Process with FDA (1H 2014)
•Alpha commercial prototype design completed
•Alpha commercial prototype built
•Tissue testing continues
Initiation of Outside U.S. Approval Process (1H 2015)
•Tissue validation study completed
•Product design and design verification completed
Initiation of Outside U.S. Initial Commercial Launch Process (1H 2015)
•Application for CE Mark to European regulatory agencies submitted
•CE Mark approval from European regulators obtained
•Limited commercial launch in Europe undertaken
•Human trials in U.S. and final FDA approval submission process commence
Initiation of FDA 510(K) Clearance Process (2H 2015)
•Final phase of FDA approval process completed
•Limited commercial product launch in U.S. undertaken
•Shift to high volume manufacturing initiated
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM